Cargando…
Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes
BACKGROUND: The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and their care partners. The objective of this qualitative study phase was to iden...
Autores principales: | DiBenedetti, Dana B., Slota, Christina, Wronski, Samantha L., Vradenburg, George, Comer, Meryl, Callahan, Leigh F., Winfield, John, Rubino, Ivana, Krasa, Holly B., Hartry, Ann, Wieberg, Dan, Kremer, Ian N., Lappin, Debra, Martin, Allison D., Frangiosa, Terry, Biggar, Virginia, Hauber, Brett |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393916/ https://www.ncbi.nlm.nih.gov/pubmed/32731886 http://dx.doi.org/10.1186/s13195-020-00659-6 |
Ejemplares similares
-
Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis
por: Hauber, Brett, et al.
Publicado: (2023) -
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
por: DiBenedetti, Dana B., et al.
Publicado: (2023) -
A Path to Early Diagnosis of MCI and Dementia: Integrating myMemCheck Into the Primary Care Workflow
por: Mansbach, William, et al.
Publicado: (2020) -
Caring for Dementia Caregivers: Understanding Caregiver Stress During
the COVID-19 Pandemic
por: Lancashire, Lee, et al.
Publicado: (2023) -
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
por: Llorca, Pierre-Michel, et al.
Publicado: (2017)